#Third Party Pharma Manufacturer in HP

[suavehealthcare]

Comprehensive Guide About Third Party Pharma Manufacturer in Himachal Pradesh

Himachal Pradesh offers a conducive environment for pharma manufacturing, which attracts various companies to manufacture their products through third-party contracts. Suave Healthcare is one of the leading provider of third party pharma manufacturer in Himachal Pradesh, offers various advantages to businesses looking to outsource their production. Read more Mail: suavehealthcare1@gmail.com Contact: +91-9218562669

[jmlabs]

Looking for reliable Third Party Pharma Manufacturing Company in Ahmedabad? We are a leading third-party pharma manufacturing company, offering quality solutions to meet your pharmaceutical production needs. The third-party pharmaceutical manufacturing business is the best way for the pharma business, especially in today’s time.

Get In Touch

Address: Vill. Bhanat,P.O. Ghatti, Subathu Road,Solan (HP)

Email: jmhealthcare@yahoo.com

Mobile: +91-9216310884

[doyothirdpartymunuifacture]

Best Pharma third party manufacturing in India

Best Pharma third party manufacturing in India

WHO, GMP, and ISO Certified Third Party Manufacturing Pharma Companies in India. DOYO Pharma Company.

Third-party pharma manufacturers in India - In the current business scenario, getting involved in third party pharma manufacturing in India can be a daunting task as it involves the continuous development of new components and technologies to meet the ever-changing demands of customers DOYO company Is a Baddi (HP) based third / third party manufacturing pharma company. DOYO has been involved in pharma third-party manufacturing in India since 2017. We have full experience in third-party manufacturing at Belt Pharma, and we are known for providing high-quality products to our business partners. Our manufacturing facility is ISO 9001: 2008 and WHO-GMP certified. With the increasing complexity of pharmaceutical products, manual operating methods are being replaced by high-tech manufacturing techniques. And obviously, it requires a lot of investment and special resources.

Soft-gel third party manufacturer

Softgel Third Party Manufacturer - In addition to making common medicines for our customers, we are also the number one soft gel third-party manufacturer in India. DOYO is one of the top soft gelatin formulation manufacturers in the excise-free zone. Due to years of experience, the top third party manufacturing pharmaceutical company can provide high-quality pharmaceutical drugs. Our manufactured pharmaceutical drugs Tickle medicines are very well accepted by the medical fraternity. We are known for consistently providing high-quality products in attractive packaging. As a Softgel third party pharma manufacturer in India, we are committed to providing you with high-quality pharmaceutical products. As discussed, making medicines involves a huge investment, and will consume your precious time.

But once you join us, we (the top soft-gel third-party manufacturers) promise you that you will take all the headaches of drug manufacturing away from your review so that you can further your business You will be able to focus on important aspects such as pharmaceutical marketing and management. Pharmaceutical supply chain without any tension of manufacturing pharmaceutical drugs or third party manufacturing.

Third-party pharma manufacturers

DOYO Is a leading ISO-certified third party pharma manufacturer in India. The top company is engaged in offering pharmaceutical products manufacturing to our esteemed clients. We are the fastest growing pharmaceutical tackle manufacturing industry involved in providing third party pharmaceutical tackle manufacturing services to our global customers. We manufacture a wide range of third party pharmaceutical products in the Excise Free Zone which enables our customers to generate the expected earnings and reputation in the medical industry. Well-known third-party pharmaceutical manufacturers provide full-fledged promotional assistance to customers to set up their business at reasonable rates. And our services can be accessed by simply filling out an online form on our official website.

If you are still looking for third party manufacturing pharmaceutical companies or top third party manufacturing companies in India, contact DOYO or our inquiry form or + 91 9814135709.

[healthcarebiz]

China Pharma Holdings, Inc. Reports First Quarter 2017 Financial Results

HAIKOU CITY, China, May 12, 2017 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE MKT: CPHI) ("China Pharma,"  the "Company" or "We"), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the quarter ended March 31, 2017.

First Quarter Highlights

Revenue decreased 9.8% to $3.3 million in first quarter 2017 from $3.6 million in the same period of 2016;

Gross profit margin was 21.9% in first quarter 2017, compared to 17.6% in the same period of 2016.

Loss from operations was $0.8 million in first quarter 2017 compared to $1.3 million in the same period of 2016, a decrease of $0.5 million;

Net loss was $1.0 million in first quarter 2017 compared to $1.6 million in the same period of 2016.  Loss per common share was $(0.02) per basic and diluted share in first quarter 2017 compared with $(0.04) per basic and diluted share in the same period of 2016.

"We experienced a slight revenue decrease in the first quarter of 2017 compared to the same period last year, which was mainly due to a more significant impact from an earlier Spring Festival holiday in 2017. However, we believed that our overall financial performance has improved, taking into consideration the increased gross profit margin and decreased net loss," said Ms. Zhilin Li, China Pharma's Chairman and CEO.  Ms. Li continued, "Nevertheless, increasing sales remains our top priority. Management will continue to vigorously promote sales by actively participating in the recent opening of the new provincial drug tender offer and further exploring basic medical market. We continue to believe that demand for pharmaceutical products is huge and steady in China. The ongoing generic drug consistency evaluations and reform of China's drug production registration and review policies will have a major impact on the future development of our industry and may change its business patterns. We will continue to actively adapt to state policy guidance and further evaluate market conditions for our current existing products, pipeline products, and competition in the market in order to optimize our development strategy."

First Quarter Results

Revenue decreased by 9.8% to $3.3 million for the three months ended March 31, 2017, as compared to $3.6 million for the three months ended March 31, 2016. This decrease was primarily due to the impact from Chinese Spring Festival on purchase and logistic activities.

Gross profit for the three months ended March 31, 2017 was $0.7 million, compared to $0.6 million in the same period last year. Our gross profit margin in the three months ended March 31, 2017 was 21.9% compared to 17.6% in the same period last year. This increase was primarily due to the increase in gross profit margins of our major products in this period.

Our selling expenses for the three months ended March 31, 2017 were $0.7 million, a decrease of $0.3 million, compared to $1.0 million for the three months ended March 31, 2016. Selling expenses accounted for 21.8% of the total revenue in the three months ended March 31, 2017 compared to 26.6% in the same period last year.  Because of adjustments in our sales practices resulting from health-care reform policies, despite the overall decrease in sales, we may require additional personnel and expenses to support our sales and the collection of accounts receivable.

Our general and administrative expenses for the three months ended March 31, 2017 were $0.4 million, which represented an increase of $0.1 million compared to $0.3 million in the same period last year. General and administrative expenses accounted for 12.7% and 8.7% of our total revenues in three months ended March 31, 2017 and 2016, respectively. This increase was primarily due to several major payments for listing maintenance happened in the three months ended March 31, 2017.

Our bad debt expenses for the three months ended March 31, 2017 was $0.4 million, which represented a decrease of $0.2 million compared to $0.6 million in the same period last year. The decline in our bad debt expenses was mainly the result of the decline in our revenues in recent years, which also led to the corresponding decline in the net amount of accounts receivable aging over one year (according to our current accounting policy, we are required to recognize a 70% bad debt allowance).

Our income tax expense was $0.03 million and $0.02 million for the three months ended March 31, 2017 and 2016, respectively. The expense arose as a result of certain deferred tax liabilities recognized in prior years. We renewed our "National High-Tech Enterprise" status with the Chinese government in the third quarter of 2013. With this designation, for the years ending December 31, 2015 and 2016, we enjoy a preferential tax rate of 15%, which is notably lower than the statutory income tax rate of 25%. However, our recent net loss results have put the Company in an unfavorable position for the potential renewal of "National High-Tech Enterprise" status in 2017, and after evaluating the feasibility of such a renewal, the Company has decided not to renew this status. As a result, our tax rate for 2017 and the foreseeable future will be 25%.

Net loss for the first quarter 2017 was $1.0 million, or $(0.02) per basic and diluted share, compared to net loss of $1.6 million, or $(0.04) per basic and diluted share for the same period of 2016. The decrease in net loss was mainly a result of the increase in gross profit margin and decrease in bad debt expenses.

Financial Condition

As of March 31, 2017, the Company had cash and cash equivalents of $2.5 million compared to $2.7 million as of December 31, 2016. Working capital decreased to $6.9 million as of March 31, 2017 from $7.1 million as of December 31, 2016; and the current ratio was 1.7 times in both March 31, 2017 and December 31, 2016, respectively.

Our accounts receivable balance decreased to $3.7 million as of March 31, 2017 from $4.0 million as of December 31, 2016.

Conference Call

The Company will hold a conference call at 8:30 am E.T. on May 12, 2017 to discuss the results of first quarter 2017. Listeners may access the call by dialing 1-866-519-4004 or 65-671-350-90 for international callers, Conference ID # 20452439.  A replay of the call will be accessible through May 20, 2017 by dialing 1-855-452-5696 or 61-281-990-299 for international callers, Conference ID # 20452439.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit http://ift.tt/12Ilc1R. The Company routinely posts important information on its website.

Safe Harbor Statement 

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as the achievability of financial guidance, success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations except as required by applicable law or regulation.

Contact:

China Pharma Holdings, Inc.  Ms. Diana Na Huang                          Phone:  +86-898-6681-1730 (China)                                          Email: hps@chinapharmaholdings.com        

 - FINANCIAL TABLES FOLLOW - 

    CHINA PHARMA HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

March 31,

December 31,

2017

2016

(Unaudited)

ASSETS

Current Assets:

Cash and cash equivalents

$      2,523,541

$      2,665,802

Restricted cash

1,718,823

1,088,879

Banker's acceptances

14,513

-

Trade accounts receivable, less allowance for doubtful

accounts of $16,161,252 and $15,664,496, respectively

3,703,593

3,999,809

Other receivables, less allowance for doubtful

accounts of $56,157 and $71,548, respectively

272,097

224,373

Advances to suppliers

2,036,758

2,003,792

Inventory

6,985,965

7,310,939

Prepaid expenses

205,293

226,357

Total Current Assets

17,460,583

17,519,951

Advances for purchases of intangible assets

35,771,976

35,498,059

Property and equipment, net

24,422,373

24,967,448

Intangible assets, net

488,044

534,682

TOTAL ASSETS

$    78,142,976

$    78,520,140

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:

Trade accounts payable

$      2,877,412

$      3,060,374

Accrued expenses

90,232

139,830

Other payables

2,355,365

2,502,694

Advances from customers

703,915

811,232

Other payables - related parties

1,354,567

1,354,567

Current portion of construction loan facility

1,440,154

1,440,154

Bankers' acceptance notes payable

1,718,823

1,088,879

Total Current Liabilities

10,540,468

10,397,730

Non-current Liabilities:

Construction loan facility

8,573,590

8,640,927

Deferred tax liability

607,090

572,349

Total Liabilities

19,721,148

19,611,006

Stockholders' Equity:

Preferred stock, $0.001 par value; 5,000,000 shares authorized;

no shares issued or outstanding

-

-

Common stock, $0.001 par value; 95,000,000 shares authorized;

43,579,557 shares and 43,579,557 shares outstanding, respectively

43,580

43,580

Additional paid-in capital

23,590,204

23,590,204

Retained earnings

23,790,476

24,757,374

Accumulated other comprehensive income

10,997,568

10,517,976

Total Stockholders' Equity

58,421,828

58,909,134

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$    78,142,976

$    78,520,140

  CHINA PHARMA HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE INCOME (LOSS)

(Unaudited)

For the Three Months

Ended March 31,

2017

2016

Revenue

$        3,285,203

$         3,640,494

Cost of revenue

2,567,350

2,999,675

Gross profit

717,853

640,819

Operating expenses:

Selling expenses

717,637

968,507

General and administrative expenses

416,726

318,930

Research and development expenses

26,060

93,433

Bad debt expense

360,063

581,300

Total operating expenses

1,520,486

1,962,170

Loss from operations

(802,633)

(1,321,351)

Other income (expense):

Interest income

5,033

33,592

Interest expense

(138,964)

(242,309)

Net other expense

(133,931)

(208,717)

Loss before income taxes

(936,564)

(1,530,068)

Income tax  expense

(30,334)

(22,828)

Net loss

(966,898)

(1,552,896)

Other comprehensive income - foreign currency

translation adjustment

479,592

480,430

Comprehensive loss

$          (487,306)

$       (1,072,466)

Loss per share:

Basic and diluted

$                (0.02)

$                (0.04)

Weighted average shares outstanding

43,579,557

43,579,557

      CHINA PHARMA HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

For the Three Months

Ended March 31,

2017

2016

Cash Flows from Operating Activities:

Net loss

$        (966,898)

$     (1,552,896)

Depreciation and amortization

815,394

857,195

Bad debt expense

360,063

581,300

Deferred income taxes

30,334

22,828

Changes in assets and liabilities:

Trade accounts and other receivables

(261,377)

(61,069)

Advances to suppliers

(17,509)

(92,039)

Inventory

549,500

215,496

Trade accounts payable

(206,599)

888,212

Accrued taxes payable

(71,575)

(53,955)

Other payables and accrued expenses

(130,772)

25,514

Advances from customers

(113,615)

328,354

Prepaid expenses

22,818

144,262

Net Cash Provided by Operating Activities

9,764

1,303,202

Cash Flows from Investing Activities:

Purchases of property and equipment

(26,628)

(39,248)

Net Cash Used in Investing Activities

(26,628)

(39,248)

Cash Flows from Financing Activities:

Payments of construction term loan

(145,176)

(305,835)

Net Cash Used in Financing Activity

(145,176)

(305,835)

Effect of Exchange Rate Changes on Cash

19,779

54,898

Net (Decrease) Increase in Cash and Cash Equivalents

(142,261)

1,013,017

Cash and Cash Equivalents at Beginning of Period

2,665,802

6,248,760

Cash and Cash Equivalents at End of Period

$       2,523,541

$       7,261,777

Supplemental Cash Flow Information:

Cash paid for interest

$          138,964

$          242,309

Supplemental Noncash Investing and Financing Activities:

Issuance of banker's acceptances

$          621,753

$                      -

Accounts receivable collected with banker's acceptances

182,499

517,770

Inventory purchased with banker's acceptances

$          167,981

$          403,081

To view the original version on PR Newswire, visit:http://ift.tt/2q9NkuU

Read this news on PR Newswire Asia website: China Pharma Holdings, Inc. Reports First Quarter 2017 Financial Results

[suavehealthcare]

Third Party Pharma Manufacturer in Himachal Pradesh | Suave Healthcare

Sauve Healthcare is a third party pharmaceutical manufacturer in Himachal Pradesh, India. We offer premium quality products with unmatched customer service and reliable delivery. Our extensive range of products is manufactured in compliance with GMP standards. Get in touch to find out more about our services.

Visit: https://www.suavehealthcare.com Contact: +91-9218562669 Mail: suavehealthcare1@gmail.com

[jmlabs]

Third Party Pharma Manufacturing Company In Ahmedabad || JM Laboratories

JM Laboratories is a leading Third Party Pharma Manufacturing Company in Ahmedabad. We provide customized solutions for manufacturing a wide range of pharmaceutical products, including tablets, capsules, injections, syrups, and more. Our strict adherence to quality control measures ensures that our products meet the highest industry standards. We also prioritize timely delivery to fulfill all orders promptly. If you are looking for reliable third-party pharma manufacturing services in Ahmedabad, contact JM Laboratories today to learn more about how we can help your business grow.

Contact Us

Mobile Number: 9216310884

Address: Vill. Bhanat, P.O. Ghatti, Subathu Road, Solan (HP) 173211

Email ID: jmhealthcare@yahoo.com

[doyothirdpartymunuifacture]

Third Party Manufacturer in Baddi

Third Party Manufacturer in Baddi - DOYO. India is one of the fastest growing pharmaceutical manufacturing companies based in Badi, Nalagarh (HP) is committed to providing innovative, quality and affordable medicines for healthy living. Maintain the highest standards of quality; The product pharma meets the appropriate pharmacopoeial standards and legal requirements. In addition, the company ensures that all steps involved in the design, development and manufacture of a product lead to an appropriate level of quality performance in the market.

We are a leading third party manufacturer, supplier, and exporter of a variety of pharmaceutical drugs such as tablets, capsules, syrups, dry syrups and dry injections, etc., which are applicable for the treatment of various ailments. With a 15-year history of drug distribution and manufacturing, with training in the manufacture of 1000 million tablets, 200 million capsules, 50 million oral fluids and 10 million beta-lactam dry syrups, we have estimated that drugs Construction will move forward in the country, where as a result of sharp commodity prices and declining profits. As such, we created our own branded and technology division and since then have directed most of our R&D budgets to developing brand new products. There are many pharmaceutical companies that do not have their own manufacturing unit so they are affiliated with us for third party pharma manufacturing services.

As we leverage our 5 years of manufacturing experience for selected new product opportunities and distribution for authorized sales, marketing and branding companies, our emphasis has shifted to our branded and technology pipelines. That is why we are the top third party manufacturing company in India. Feel free to contact us at any time if you are planning on sourcing our construction work.

For  more info:- https://doyo.co.in/third-party-pharma-manufacturing-company-in-ndia/